Healthcare professionals must communicate with patients and relatives. They must enable informed, realistic and appropriate decisions in end-of-life pharmacotherapy

Abstract

Commentary on: Morin L, Wastesson JW, Laroche ML, et al . How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med 2019;33:1080–90. doi: 10.1177/0269216319854013. Use of a variety of drugs (polypharmacy) is required to manage complex disease processes. At the end of life, the focus of ‘treatment’ changes from extending survival to symptom management—therefore, aims of treatments change, requiring different pharmaceutical …